[Ip-health] REMINDER: MSF's Launch Report- COUGH UP FOR TB- European Parliament Nov 12th. Lunch Debate" How much does the European Commission pay for Turberculosis R&D?"

[Alexandra HEUMBER]

[ Converted text/html to text/plain ]

The Honourable Members of the European Parliament

Carl Schlyter MEP (Green party- Sweden),

Dorette Corbey MEP (PSE- Netherlands),

Luisa Morgantini MEP (GUE/NGL - Italy),



are pleased to host the launch of a report by M=E9decins Sans Fronti=E8res:



How much does the European Commission pay

for tuberculosis R&D?



12:30-2pm, Wednesday 12 th November 2008

European Parliament,  Room A5G2

Sandwiches will be provided





Chair Carl Schlyter, MEP



Opening remarks Luisa Morgantini, MEP



How much does the European Commission pay for tuberculosis R&D?

Presentation of the M=E9decins Sans Fronti=E8res, Access to Essential Medic=
ines
Campaign Report:

Dr. Tido von Schoen-Angerer, Director, MSF Access to Essential Medicines
Campaign

Spring Gombe, Main author of the report, Consultant to MSF



Respondents:

Prof. Stewart Cole, Head of Laboratories, Ecole Publique Polytechnique
F=E9d=E9rale de Lausanne

Louise Baker, Senior Strategist, Stop TB partnership

Dr. Frauke Jochims, TB advisor, M=E9decins Sans Fronti=E8res



  Discussion



Closing remarks Dorette Corbey, MEP





A recent report [1] [1]notes how ?Europe?s research funding situation is a
jigsaw puzzle of complexity, lack of transparency, lack of coordination, an=
d
lack of clear priorities. With few exceptions most of the rich EU countries
were not in a position to either report on or increase their investments in=
 TB
research.?



M=E9decins Sans Fronti=E8res has explored the European Commission?s contrib=
ution,
and analyses why funding dedicated to R&D for neglected diseases such as TB=
 is
still grossly insufficient in comparison to the need.    Why so?   What wou=
ld
the EC?s fair share be?   How can funding streams be improved so that the
money matches the needs?   What needs to happen?



Join us to discuss these and other crucial questions.

Please RSVP confirming your attendance to mai.do@paris.msf.org before Novem=
ber
10, 2008.

---------------------------------------------------------------------------=
---

[1] [2]Treatment Action Group. TB R&D: A critical Analysis of funding trend=
s
2005-2006
____________________________________
Alexandra Heumber
IP Policy Adviser
M=E9decins Sans Fronti=E8res
Access to Essential Medicines Campaign
Rue Dupr=E9, 94. 1090 Brussels
++32 (0) 2 474 75 09 (Dir off)
++ 32 (0) 479 514 900 (Mob)
++ 32 (0) 2 474 75 75 (Fax)

=3D=3D=3DReferences:=3D=3D=3D
  1. http://mail.brussels.msf.org/mail/aheumber.nsf/($Sent)/497190582EDDEF1=
DC12574FD003C409A/?OpenDocument&PresetFields=3Ds_ViewName;(%24Sent),h_F=
olderStorage;(%24Sent),s_FromMail;1,s_SortBy;3,s_UnreadOnly;0#_ftn1
  2. http://mail.brussels.msf.org/mail/aheumber.nsf/($Sent)/497190582EDDEF1=
DC12574FD003C409A/?OpenDocument&PresetFields=3Ds_ViewName;(%24Sent),h_F=
olderStorage;(%24Sent),s_FromMail;1,s_SortBy;3,s_UnreadOnly;0#_ftnref1